Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06056921 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Name: Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease — clinical trial record (NCT06056921)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusUnknown

PhasePhase 1

SponsorChongqing Precision Biotech Co., Ltd

Started2023-08-31

View on ClinicalTrials.gov ↗

Record status

This record was last updated September 28, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06

Trial status changed: Recruiting → Unknown

Chongqing Precision Biotech Co., Ltd

36 trials monitored

See 1 trial at risk

Lupus (SLE)

648 trials monitored

See 25 trials at risk

Scleroderma

302 trials monitored

See 9 trials at risk

This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease

Trial Details

NCT Number	NCT06056921
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Enrollment	24 participants
Start Date	2023-08-31
Primary Completion	2025-12-31 (estimated)
Study Completion	2026-08-31 (estimated)
Updated on ClinicalTrials.gov	2023-09-28